BCHE and Alzheimer disease: Beside selectivity, the tested biscarbamates are very fast BChE inhibitors whose inhibition potency is equally or up to 690 times more potent than rivastigmine’s, an ethylmethyl carbamate currently in use for treatment of AD and approved by the FDA.